Novo Nordisk previously claimed to have been alarmed by "reports of medical spas, weight loss clinics, pharmacies, and other companies" selling compounded semaglutide to patients on the grounds that they "do not have the same safety, quality, and effectiveness assurances as Novo Nordisk's FDA-approved drugs." Compounding pharmacies are mostly regulated at the state level by boards of pharmacy
Eventually, Wegovy launched as a weight-loss-indicated variation of Ozempic, spurring a slight acceleration in the number of written GLP-1 prescriptions (3% compound monthly growth grate, June 2021 to May 2022)
doi: 10.1016/j.envint.2019.105298, 190 Perez-VazquezA.BarcielaP.PrietoM
Exendin-4 is a peptide that shares 53% sequence homology with human GLP-1 and can bind and activate GLP-1 receptors with similar potency to GLP-1RAs
Three separate vials win on flexibility
One experiment in rats found improved healing of a severed Achilles tendon [5]